Ildong Holdings Co., Ltd. (000230.KS)
KRW 6600.0
(-5.44%)
KRW 6600.0
(-5.44%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 638.44 Billion KRW | -5.49% |
| 2022 | 675.53 Billion KRW | 14.04% |
| 2021 | 592.37 Billion KRW | -0.69% |
| 2020 | 596.46 Billion KRW | 104.12% |
| 2019 | 292.22 Billion KRW | 521.09% |
| 2018 | 47.05 Billion KRW | 14.56% |
| 2017 | 41.07 Billion KRW | 0.73% |
| 2016 | 40.77 Billion KRW | -91.44% |
| 2015 | 476.38 Billion KRW | 14.1% |
| 2014 | 417.51 Billion KRW | 5.64% |
| 2013 | 395.23 Billion KRW | 8.94% |
| 2012 | 362.78 Billion KRW | 4.11% |
| 2011 | 348.46 Billion KRW | 0.38% |
| 2010 | 347.15 Billion KRW | -12.32% |
| 2009 | 395.94 Billion KRW | 5.04% |
| 2008 | 376.93 Billion KRW | 4.25% |
| 2007 | 361.58 Billion KRW | 4.93% |
| 2006 | 344.57 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 168.15 Billion KRW | 3.89% |
| 2024 Q1 | 161.85 Billion KRW | 2.06% |
| 2024 Q3 | 166.56 Billion KRW | -0.94% |
| 2023 Q3 | 160.05 Billion KRW | -3.44% |
| 2023 Q2 | 165.75 Billion KRW | 7.59% |
| 2023 Q1 | 154.05 Billion KRW | -4.56% |
| 2023 Q4 | 158.58 Billion KRW | -0.92% |
| 2023 FY | 638.44 Billion KRW | -5.49% |
| 2022 FY | 675.53 Billion KRW | 14.04% |
| 2022 Q1 | 168.07 Billion KRW | 11.59% |
| 2022 Q2 | 171.83 Billion KRW | 2.23% |
| 2022 Q3 | 174.21 Billion KRW | 1.39% |
| 2022 Q4 | 161.41 Billion KRW | -7.35% |
| 2021 Q3 | 150.88 Billion KRW | 1.31% |
| 2021 Q4 | 150.61 Billion KRW | -0.18% |
| 2021 Q1 | 141.94 Billion KRW | -3.45% |
| 2021 Q2 | 148.92 Billion KRW | 4.92% |
| 2021 FY | 592.37 Billion KRW | -0.69% |
| 2020 Q4 | 147.01 Billion KRW | -4.22% |
| 2020 FY | 596.46 Billion KRW | 104.12% |
| 2020 Q1 | 148.61 Billion KRW | 8.59% |
| 2020 Q2 | 147.33 Billion KRW | -0.86% |
| 2020 Q3 | 153.49 Billion KRW | 4.18% |
| 2019 Q3 | 127.36 Billion KRW | 839.92% |
| 2019 FY | 292.22 Billion KRW | 521.09% |
| 2019 Q2 | 13.55 Billion KRW | -6.18% |
| 2019 Q4 | 136.86 Billion KRW | 7.46% |
| 2019 Q1 | 14.44 Billion KRW | 14.71% |
| 2018 Q3 | 12.33 Billion KRW | 8.31% |
| 2018 Q1 | 10.73 Billion KRW | 18.0% |
| 2018 FY | 47.05 Billion KRW | 14.56% |
| 2018 Q4 | 12.59 Billion KRW | 2.07% |
| 2018 Q2 | 11.39 Billion KRW | 6.14% |
| 2017 Q3 | 10.45 Billion KRW | -8.59% |
| 2017 Q2 | 11.44 Billion KRW | 13.54% |
| 2017 Q1 | 10.07 Billion KRW | 32.36% |
| 2017 FY | 41.07 Billion KRW | 0.73% |
| 2017 Q4 | 9.09 Billion KRW | -13.04% |
| 2016 Q4 | 7.61 Billion KRW | -24.15% |
| 2016 FY | 40.77 Billion KRW | -91.44% |
| 2016 Q3 | 10.03 Billion KRW | -16.63% |
| 2016 Q2 | 12.03 Billion KRW | -90.53% |
| 2016 Q1 | 127.07 Billion KRW | 0.83% |
| 2015 FY | 476.38 Billion KRW | 14.1% |
| 2015 Q1 | 119 Billion KRW | 3.07% |
| 2015 Q2 | 111.72 Billion KRW | -6.12% |
| 2015 Q3 | 119.63 Billion KRW | 7.08% |
| 2015 Q4 | 126.02 Billion KRW | 5.35% |
| 2014 Q4 | 115.46 Billion KRW | 6.82% |
| 2014 Q3 | 108.09 Billion KRW | 4.21% |
| 2014 Q2 | 103.72 Billion KRW | 14.95% |
| 2014 Q1 | 90.23 Billion KRW | -16.8% |
| 2014 FY | 417.51 Billion KRW | 5.64% |
| 2013 FY | 395.23 Billion KRW | 8.94% |
| 2013 Q4 | 108.45 Billion KRW | -0.52% |
| 2013 Q1 | 85.73 Billion KRW | -14.38% |
| 2013 Q3 | 109.02 Billion KRW | 18.48% |
| 2013 Q2 | 92.01 Billion KRW | 7.33% |
| 2012 FY | 362.78 Billion KRW | 4.11% |
| 2012 Q4 | 100.13 Billion KRW | 11.85% |
| 2012 Q3 | 89.52 Billion KRW | -6.85% |
| 2012 Q2 | 96.11 Billion KRW | 29.02% |
| 2012 Q1 | 74.49 Billion KRW | 0.0% |
| 2011 FY | 348.46 Billion KRW | 0.38% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q3 | 85.28 Billion KRW | 1.3% |
| 2011 Q1 | 80.71 Billion KRW | 0.0% |
| 2011 Q2 | 84.19 Billion KRW | 4.3% |
| 2010 Q1 | - KRW | -100.0% |
| 2010 FY | 347.15 Billion KRW | -12.32% |
| 2010 Q3 | 84.84 Billion KRW | 11.56% |
| 2010 Q2 | 76.05 Billion KRW | 0.0% |
| 2009 FY | 395.94 Billion KRW | 5.04% |
| 2009 Q2 | 70.32 Billion KRW | 0.0% |
| 2009 Q3 | 79.19 Billion KRW | 12.61% |
| 2009 Q4 | 81.16 Billion KRW | 2.5% |
| 2009 Q1 | - KRW | -100.0% |
| 2008 Q4 | 71.9 Billion KRW | -4.95% |
| 2008 Q2 | 68.65 Billion KRW | 0.0% |
| 2008 Q3 | 75.65 Billion KRW | 10.19% |
| 2008 Q1 | - KRW | -100.0% |
| 2008 FY | 376.93 Billion KRW | 4.25% |
| 2007 Q3 | 67.67 Billion KRW | 8.99% |
| 2007 FY | 361.58 Billion KRW | 4.93% |
| 2007 Q4 | 64.21 Billion KRW | -5.12% |
| 2007 Q2 | 62.09 Billion KRW | 0.0% |
| 2006 FY | 344.57 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -365.308% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 43.6% |
| HANDOK Inc. | 522.74 Billion KRW | -22.135% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -371.622% |
| Yuhan Corporation | 1858.98 Billion KRW | 65.656% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 3.845% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -1128.846% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 57.177% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -373.24% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -72.303% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -620.648% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -276.516% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -184.441% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -365.308% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -717.964% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -322.614% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -630.793% |
| JW Holdings Corporation | 928.07 Billion KRW | 31.207% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | -6.274% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 61.756% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 14.706% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -218.859% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -253.197% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -225.165% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 12.107% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -365.308% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 57.843% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 53.579% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 14.706% |
| Yuhan Corporation | 1858.98 Billion KRW | 65.656% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 19.663% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -171.793% |
| Suheung Co., Ltd. | 594.56 Billion KRW | -7.38% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 14.706% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | -118.55% |
| Korea United Pharm Inc. | 278.94 Billion KRW | -128.881% |
| CKD Bio Corp. | 160.35 Billion KRW | -298.152% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | -21.159% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | -76.802% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -177.112% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -218.859% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 27.431% |
| Boryung Corporation | 859.62 Billion KRW | 25.73% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -406.993% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -72.303% |
| JW Lifescience Corporation | 206.86 Billion KRW | -208.637% |